S&P 500   4,005.59 (+0.07%)
DOW   32,522.38 (-0.12%)
QQQ   311.03 (+0.22%)
AAPL   160.14 (+0.54%)
MSFT   276.13 (+0.86%)
META   202.54 (+0.19%)
GOOGL   105.11 (+0.18%)
AMZN   100.14 (-0.47%)
TSLA   197.17 (-0.21%)
NVDA   269.77 (+2.97%)
NIO   9.43 (+1.73%)
BABA   85.12 (+1.70%)
AMD   96.76 (+0.87%)
T   18.57 (+0.16%)
F   11.86 (+1.19%)
MU   58.69 (+0.10%)
CGC   1.97 (-0.25%)
GE   92.36 (+0.20%)
DIS   96.26 (-0.29%)
AMC   4.57 (+3.63%)
PFE   40.49 (-0.42%)
PYPL   75.70 (-1.33%)
NFLX   300.49 (-1.73%)
S&P 500   4,005.59 (+0.07%)
DOW   32,522.38 (-0.12%)
QQQ   311.03 (+0.22%)
AAPL   160.14 (+0.54%)
MSFT   276.13 (+0.86%)
META   202.54 (+0.19%)
GOOGL   105.11 (+0.18%)
AMZN   100.14 (-0.47%)
TSLA   197.17 (-0.21%)
NVDA   269.77 (+2.97%)
NIO   9.43 (+1.73%)
BABA   85.12 (+1.70%)
AMD   96.76 (+0.87%)
T   18.57 (+0.16%)
F   11.86 (+1.19%)
MU   58.69 (+0.10%)
CGC   1.97 (-0.25%)
GE   92.36 (+0.20%)
DIS   96.26 (-0.29%)
AMC   4.57 (+3.63%)
PFE   40.49 (-0.42%)
PYPL   75.70 (-1.33%)
NFLX   300.49 (-1.73%)
S&P 500   4,005.59 (+0.07%)
DOW   32,522.38 (-0.12%)
QQQ   311.03 (+0.22%)
AAPL   160.14 (+0.54%)
MSFT   276.13 (+0.86%)
META   202.54 (+0.19%)
GOOGL   105.11 (+0.18%)
AMZN   100.14 (-0.47%)
TSLA   197.17 (-0.21%)
NVDA   269.77 (+2.97%)
NIO   9.43 (+1.73%)
BABA   85.12 (+1.70%)
AMD   96.76 (+0.87%)
T   18.57 (+0.16%)
F   11.86 (+1.19%)
MU   58.69 (+0.10%)
CGC   1.97 (-0.25%)
GE   92.36 (+0.20%)
DIS   96.26 (-0.29%)
AMC   4.57 (+3.63%)
PFE   40.49 (-0.42%)
PYPL   75.70 (-1.33%)
NFLX   300.49 (-1.73%)
S&P 500   4,005.59 (+0.07%)
DOW   32,522.38 (-0.12%)
QQQ   311.03 (+0.22%)
AAPL   160.14 (+0.54%)
MSFT   276.13 (+0.86%)
META   202.54 (+0.19%)
GOOGL   105.11 (+0.18%)
AMZN   100.14 (-0.47%)
TSLA   197.17 (-0.21%)
NVDA   269.77 (+2.97%)
NIO   9.43 (+1.73%)
BABA   85.12 (+1.70%)
AMD   96.76 (+0.87%)
T   18.57 (+0.16%)
F   11.86 (+1.19%)
MU   58.69 (+0.10%)
CGC   1.97 (-0.25%)
GE   92.36 (+0.20%)
DIS   96.26 (-0.29%)
AMC   4.57 (+3.63%)
PFE   40.49 (-0.42%)
PYPL   75.70 (-1.33%)
NFLX   300.49 (-1.73%)
OTCMKTS:HLUYY

H. Lundbeck A/S - HLUYY Stock Forecast, Price & News

$22.00
-0.01 (-0.02%)
(As of 08/9/2022)
Add
Compare
Today's Range
$22.00
$24.00
50-Day Range
$22.00
$22.00
52-Week Range
$10.00
$31.55
Volume
7,500 shs
Average Volume
1,758 shs
Market Capitalization
$21.91 billion
P/E Ratio
25.00
Dividend Yield
0.91%
Price Target
$36.50

HLUYY stock logo

About H. Lundbeck A/S (OTCMKTS:HLUYY) Stock

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

Receive HLUYY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for H. Lundbeck A/S and its competitors with MarketBeat's FREE daily newsletter.

HLUYY Stock News Headlines

H. Lundbeck A/S reports FY results
H. Lundbeck A/S (HLUN-B.CO)
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
H Lundbeck B (HLUNb)
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
H. Lundbeck AS ADR (HLUYY)
H. Lundbeck A/S ADR
Global Generic Drugs Market to Reach $507.8 Billion by 2026
See More Headlines
Receive HLUYY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for H. Lundbeck A/S and its competitors with MarketBeat's FREE daily newsletter.

HLUYY Company Calendar

Last Earnings
11/04/2015
Today
3/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Private Households
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:HLUYY
CIK
N/A
Employees
5,348
Year Founded
1915

Price Target and Rating

Average Stock Price Forecast
$36.50
High Stock Price Forecast
$44.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+65.9%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$209.69 million
Pretax Margin
7.83%

Debt

Sales & Book Value

Annual Sales
$2.59 billion
Cash Flow
$3.36 per share
Book Value
$14.60 per share

Miscellaneous

Free Float
N/A
Market Cap
$21.91 billion
Optionable
Not Optionable
Beta
0.68

Social Links


Key Executives

  • Dr. Deborah Dunsire M.D. (Age 60)
    Pres & CEO
    Comp: $7.16M
  • Mr. Jacob Tolstrup (Age 50)
    Exec. VP of Commercial Operations & Chief Commercial Officer
    Comp: $888.17k
  • Mr. Lars Bang (Age 60)
    Exec. VP of Product Devel. & Supply
    Comp: $915.5k
  • Dr. Per Johan Luthman (Age 63)
    Exec. VP of R&D
    Comp: $901.84k
  • Mr. Bjorn R. Mogensen
    Sr. VP Group Fin.
  • Dr. Tarek Samad Ph.D.
    Sr. VP & Head of Research
  • Mr. Palle Holm Olesen
    Chief Specialist & VP of Investor Relations
  • Ms. Elise Hauge (Age 55)
    Exec. VP of People & Communication
  • Mr. Ole Chrintz (Age 64)
    Sr. VP of International Markets
  • Mr. Keld Flintholm Jorgensen (Age 51)
    Exec. VP of Corp. Strategy & Bus. Devel.













HLUYY Stock - Frequently Asked Questions

Should I buy or sell H. Lundbeck A/S stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for H. Lundbeck A/S in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" HLUYY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HLUYY, but not buy additional shares or sell existing shares.
View HLUYY analyst ratings
or view top-rated stocks.

What is H. Lundbeck A/S's stock price forecast for 2023?

5 Wall Street research analysts have issued 12 month price targets for H. Lundbeck A/S's shares. Their HLUYY share price forecasts range from $28.00 to $44.00. On average, they expect the company's stock price to reach $36.50 in the next twelve months. This suggests a possible upside of 65.9% from the stock's current price.
View analysts price targets for HLUYY
or view top-rated stocks among Wall Street analysts.

How have HLUYY shares performed in 2023?

H. Lundbeck A/S's stock was trading at $22.00 at the start of the year. Since then, HLUYY shares have increased by 0.0% and is now trading at $22.00.
View the best growth stocks for 2023 here
.

How were H. Lundbeck A/S's earnings last quarter?

H. Lundbeck A/S (OTCMKTS:HLUYY) posted its quarterly earnings data on Wednesday, November, 4th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.16. The firm earned $547.05 million during the quarter, compared to analyst estimates of $514.82 million. H. Lundbeck A/S had a net margin of 6.74% and a trailing twelve-month return on equity of 13.74%.

Is H. Lundbeck A/S a good dividend stock?

H. Lundbeck A/S (OTCMKTS:HLUYY) pays an annual dividend of $0.20 per share and currently has a dividend yield of 0.91%. The dividend payout ratio is 22.73%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, HLUYY will have a dividend payout ratio of 7.02% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for HLUYY.

What is H. Lundbeck A/S's stock symbol?

H. Lundbeck A/S trades on the OTCMKTS under the ticker symbol "HLUYY."

How do I buy shares of H. Lundbeck A/S?

Shares of HLUYY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is H. Lundbeck A/S's stock price today?

One share of HLUYY stock can currently be purchased for approximately $22.00.

How much money does H. Lundbeck A/S make?

H. Lundbeck A/S (OTCMKTS:HLUYY) has a market capitalization of $21.91 billion and generates $2.59 billion in revenue each year. The company earns $209.69 million in net income (profit) each year or $0.88 on an earnings per share basis.

How many employees does H. Lundbeck A/S have?

The company employs 5,348 workers across the globe.

Does H. Lundbeck A/S have any subsidiaries?
The following companies are subsidiares of H. Lundbeck A/S: Alder BioPharmaceuticals, and Prexton Therapeutics.
Read More
How can I contact H. Lundbeck A/S?

H. Lundbeck A/S's mailing address is Ottiliavej 9 Valby, Copenhagen G7, 2500. The official website for the company is www.lundbeck.com. The company can be reached via phone at (453) 630-1311, via email at palo@lundbeck.com, or via fax at 45-3630-1940.

This page (OTCMKTS:HLUYY) was last updated on 3/22/2023 by MarketBeat.com Staff